Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qdenga effectiveness in Rio de Janeiro
RBR-9j53g4rRecruiting
- Sponsor
- Secretaria Municipal de Saúde do Rio de Janeiro
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of dengue tetravalent vaccine, live, attenuated in dengue fever (2 arms), sponsored by Secretaria Municipal de Saúde do Rio de Janeiro. Primary endpoint: Vaccine effectiveness against laboratory-confirmed dengue. Started Feb 2024; status: recruiting.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on RBR-9j53g4r.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9j53g4r.